All In Biotech

Drug Trial Radar · NCT05449444

Masitinib for the Treatment of Severe Mast Cell Activation Syndrome

A 24-week, Multicenter, Randomized, Double Blind, Placebo-controlled, Dose-range Finding Phase II Study to Compare Efficacy and Safety of Oral Masitinib to Placebo in Treatment of Patients With Severe Mast Cell Activation Syndrome (MCAS) With Handicap Unresponsive to Optimal Symptomatic Treatment

Last checked: Nov 20, 2026Latest source record: Feb 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

72

Planned (sponsor's estimate)

Start

Jul 1, 2022

Primary completion

Dec 31, 2024

Study completion Dec 31, 2024

Sponsor

Lead sponsor
AB ScienceIndustry
Sponsor type
Industry
First posted
Jul 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of two dosing schemes of oral masitinib versus matching placebo in the treatment of patients suffering from severe MCAS with handicap unresponsive to optimal symptomatic treatment.

Conditions

  • Mast Cell Activation Syndrome

Interventions

  • Masitinib 4.5 mg/kg/dayDrug

    Masitinib 4.5 mg/kg/day

  • PlaceboDrug

    Matching placebo

  • Best supportive careOther

    Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, sodium cromoglicate, antidepressants, antileukotrienes, proton pump inhibitors, and corticosteroids.

  • Masitinib 6.0 mg/kg/dayDrug

    Masitinib 6.0 mg/kg/day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Confirmed response at 50%Time frame: 24 weeks

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • St Charles Clinical Research

    Weldon Spring, Missouri · Recruiting

  • Centre Hospitalier Universitaire Amiens-Picardie

    Amiens, France · Recruiting

  • Necker-Enfants Malades Hospital, Centre de référence des Mastocytoses (CEREMAST)

    Paris, France · Recruiting

  • CHU Toulouse

    Toulouse, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.